ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicInnovative solutions for host immunomodulationView all articles
Co-delivery of IL-12/IL-15/IL-18 Engineered DC Vaccines with Anti-IL-10R and Nanoconjugated Methotrexate in Melanoma
Provisionally accepted
Katarzyna Węgierek-Ciura*
Agnieszka Szczygieł
Anna Rudawska
Jagoda Mierzejewska
Joanna Rossowska
Bożena Szermer-OlearnikMarta Świtalska
Tomasz GoszczynskiElżbieta Pajtasz-Piasecka- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: In an immunosuppressive microenvironment created by melanoma cells, interleukin (IL)-10 can promote tumor growth and impair the function of antigen-presenting cells, particularly dendritic cells. One of the leading strategies to counteract IL-10's action is the administration of antibodies against its receptor. The tumor microenvironment can also be modulated by cytokines and/or cellular vaccines such as modified dendritic cells that overproduce IL-12, IL-15/IL-15Rα, and IL-18. These cellular vaccines serve as a source of cytokines and stimulate the immune system by presenting tumor antigens to lymphocytes. Furthermore, the efficacy of the dendritic cell vaccine can be achieved through the nanoconjugate of methotrexate and hydroxyethyl starch (HES-MTX), which reduces the activity of IL-10 and eliminates immunosuppressive cells. Methods: Two experiments were conducted: one focusing on immunotherapy and the other on chemoimmunotherapy. The immunotherapy involved two administrations of cellular vaccines, preceded by anti-IL-10R antibody treatment. The chemoimmunotherapy additionally included a single administration of the HES-MTX nanoconjugate. The effectiveness of both therapies was evaluated through tumor growth inhibition measurements and analysis of lymphoid and myeloid cell populations in tumor tissues. Additionally, subpopulations of restimulated splenocytes were analyzed, and the production levels of interferon gamma (IFN-γ), IL-10, and IL-4 were evaluated. Results: Modified dendritic cells, which carry proinflammatory cytokines, were used in immuno- and chemoimmunotherapeutic experiments. The developed therapies effectively inhibited tumor growth, but the rate of tumor growth depended on the type of vaccine used. Incorporating the nanoconjugate prior to immunological treatment primarily reduced the population of suppressor cells. The most effective treatment was observed in two cases: as a result of immunotherapy including the use of a two-component vaccine DC/IL-12/TAg + DC/IL-18/TAg (TGI 62.3%) or after administration of HES-MTX nanoconjugate followed by immunotherapy with three-component vaccine - DC/IL-12/TAg + DC/IL-15/IL-15Rα/TAg + DC/IL-18/TAg, (TGI 59.1%).
Keywords: anti-IL-10R antibodies, B16, Dendritic Cells, Interleukin 12, Interleukin 15, Interleukin 18, Melanoma, methotrexate nanoconjugate
Received: 23 Dec 2025; Accepted: 12 Feb 2026.
Copyright: © 2026 Węgierek-Ciura, Szczygieł, Rudawska, Mierzejewska, Rossowska, Szermer-Olearnik, Świtalska, Goszczynski and Pajtasz-Piasecka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Katarzyna Węgierek-Ciura
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.